



## Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

June 6, 2022

BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences:

**Event:** Jefferies Healthcare Conference

**Date:** Thursday, June 9, 2022

**Fireside Chat Webcast Time:** 4:30 PM ET

**Event:** Goldman Sachs 43rd Annual Global Healthcare Conference

**Date:** Wednesday, June 15, 2022

**Fireside Chat Webcast Time:** 8:00 AM PT/ 11:00 AM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the "Events and Publications" tab on the investor relations section of the Centessa Pharmaceuticals website at [Events & Presentations | Centessa Pharmaceuticals](#).

### About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc ("Centessa") is a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. For more information, visit [www.centessa.com](http://www.centessa.com), which does not form part of this release.

### Contact:

Kristen K. Sheppard, Esq.  
SVP of Investor Relations  
[investors@centessa.com](mailto:investors@centessa.com)